- Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) signed an agreement to advance Marengo Therapeutics two preclinical precision immuno-oncology candidates into clinic.
- Under the agreement, Ipsen will pay $45M upfront, with potential of up to a total of ~$1.59B if all milestones are met, plus royalty payments.
- The companies said Marengo will lead the preclinical development efforts and will expense related costs until the filing of an investigational new drug (IND) application to the FDA.
- Ipsen will assume responsibilities for clinical development and commercialization.
- The companies noted that the two candidates were generated using Marengo’s preclinical Selective T Cell Activation Repertoire (STAR) platform.
For further details see:
Ipsen to pay $45M upfront to advance Marengo's 2 immuno-oncology candidates